Phaseline

Companies › REGENXBIO

REGENXBIO: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 2, 1 Phase 3; Neurology, Metabolic and endocrine; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
RGX-121-3102
Recombinant adeno-associated virus serotype 9 (AAV9) delivering human iduronate-2-sulfatas
IDSPhase 3MPS II; Mucopolysaccharidosis Type II (MPS II)Apr 2028
RGX-202
Recombinant AAV8 gene therapy delivering novel microdystrophin transgene with C-terminal d
DMDPhase 2Duchenne Muscular DystrophyJun 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03566043RGX-121-3102Phase 2Mucopolysaccharidosis Type II (MPS II)Metabolic and endocrineNov 2023
NCT07236606RGX-121-3102Phase 3MPS IIMetabolic and endocrineApr 2028
NCT05693142RGX-202Phase 2Duchenne Muscular DystrophyNeurologyJun 2028

From the company's SEC filings

Cash and short-term investments of $251m on 2026-09-30; operating cash outflow about $134m a year; runway about 22 months at that burn, to Aug 2028; 2 of 2 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 1 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

DMD (1) IDS (1)

Companies with the same targets

Solid Biosciences NS Pharma Sarepta Therapeutics Takeda Dyne Therapeutics Avidity Biosciences Precision BioSciences Wave Life Sciences USA Belief BioMed (Beijing) Insmed Gene Therapy

Companies built like this

Dyne Therapeutics Neurogene Nippon Shinyaku Stoke Therapeutics Grace Science

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.